Suzanne Chanel

1.4k total citations
20 papers, 1.0k citations indexed

About

Suzanne Chanel is a scholar working on Molecular Biology, Hematology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Suzanne Chanel has authored 20 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Hematology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Suzanne Chanel's work include Radiopharmaceutical Chemistry and Applications (6 papers), Renal and related cancers (6 papers) and Acute Myeloid Leukemia Research (4 papers). Suzanne Chanel is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (6 papers), Renal and related cancers (6 papers) and Acute Myeloid Leukemia Research (4 papers). Suzanne Chanel collaborates with scholars based in United States, Poland and Germany. Suzanne Chanel's co-authors include David A. Scheinberg, Glenn Heller, Joseph G. Jurcic, Ellin Berman, Todd Rosenblat, P. Maslak, Robert G. Maki, Martin Fleisher, Steven L. Soignet and Raymond P. Warrell and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Suzanne Chanel

20 papers receiving 1000 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suzanne Chanel United States 12 429 428 317 232 162 20 1.0k
Kenneth B. DeSantes United States 16 322 0.8× 275 0.6× 354 1.1× 99 0.4× 354 2.2× 32 1.1k
Ciara L. Freeman United States 15 237 0.6× 279 0.7× 451 1.4× 75 0.3× 134 0.8× 87 934
J. Casper Germany 17 395 0.9× 258 0.6× 221 0.7× 27 0.1× 179 1.1× 41 970
D. J. Richel Netherlands 17 161 0.4× 240 0.6× 313 1.0× 60 0.3× 76 0.5× 29 844
Lorenzo Falchi United States 20 257 0.6× 244 0.6× 569 1.8× 169 0.7× 271 1.7× 113 1.3k
F. R. Appelbaum United States 14 552 1.3× 154 0.4× 287 0.9× 310 1.3× 149 0.9× 25 1.1k
P. Berthaud France 14 465 1.1× 248 0.6× 409 1.3× 71 0.3× 37 0.2× 42 1.3k
Hong Xie United States 13 252 0.6× 338 0.8× 406 1.3× 101 0.4× 138 0.9× 29 739
Unn‐Merete Fagerli Norway 13 261 0.6× 286 0.7× 278 0.9× 80 0.3× 77 0.5× 33 744
Mihaela Munteanu United States 14 177 0.4× 195 0.5× 538 1.7× 91 0.4× 109 0.7× 61 1.1k

Countries citing papers authored by Suzanne Chanel

Since Specialization
Citations

This map shows the geographic impact of Suzanne Chanel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Chanel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Chanel more than expected).

Fields of papers citing papers by Suzanne Chanel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Chanel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Chanel. The network helps show where Suzanne Chanel may publish in the future.

Co-authorship network of co-authors of Suzanne Chanel

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Chanel. A scholar is included among the top collaborators of Suzanne Chanel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Chanel. Suzanne Chanel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maslak, P., Tao Dao, Yvette Bernal, et al.. (2018). Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Advances. 2(3). 224–234. 121 indexed citations
2.
Maslak, P., Tao Dao, Yvette Bernal, et al.. (2016). Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR).. Journal of Clinical Oncology. 34(15_suppl). 7005–7005. 3 indexed citations
3.
Berman, Ellin, Monica Girotra, Suzanne Chanel, et al.. (2013). Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leukemia Research. 37(7). 790–794. 23 indexed citations
4.
Jurcic, Joseph G., Todd Rosenblat, Michael R. McDevitt, et al.. (2013). Targeted Alpha-particle Nano-generator Actinium-225 (225Ac)-lintuzumab (anti-CD33) in Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia. 13. S379–S380. 11 indexed citations
5.
Rosenblat, Todd, Mark G. Frattini, Suzanne Chanel, et al.. (2012). Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR). Blood. 120(21). 3624–3624. 1 indexed citations
6.
Jurcic, Joseph G., Todd Rosenblat, Michael R. McDevitt, et al.. (2011). Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML). Blood. 118(21). 768–768. 39 indexed citations
7.
Jurcic, Joseph G., Todd Rosenblat, Michael R. McDevitt, et al.. (2011). Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML).. Journal of Clinical Oncology. 29(15_suppl). 6516–6516. 23 indexed citations
8.
Rosenblat, Todd, Michael R. McDevitt, Deborah Mulford, et al.. (2010). Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia. Clinical Cancer Research. 16(21). 5303–5311. 213 indexed citations
9.
10.
Berman, Ellin, Robert G. Maki, Azeez Farooki, et al.. (2010). Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST). Blood. 116(21). 2276–2276. 1 indexed citations
11.
Iyer, Swaminathan P., Kevin R. Kelly, Mark Heaney, et al.. (2010). A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies. Blood. 116(21). 2898–2898. 6 indexed citations
12.
Rosenblat, Todd, Michael R. McDevitt, Deborah Mulford, et al.. (2008). Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 (213Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML). Blood. 112(11). 2983–2983. 4 indexed citations
13.
Krug, Lee M., P. Maslak, Leonard P. James, et al.. (2008). Pilot trial of a Wilms tumor-1 (WT1) peptide vaccine in patients with thoracic and myeloid neoplasms. Journal of Clinical Oncology. 26(15_suppl). 3051–3051. 3 indexed citations
14.
Maslak, P., Lee M. Krug, Suzanne Chanel, et al.. (2007). Pilot Study of a Wilms Tumor Protein (WT1) Heteroclitic Peptide Vaccine in Patients with Myeloid and Thoracic Neoplasms.. Blood. 110(11). 903–903. 4 indexed citations
15.
Rosenblat, Todd, Michael R. McDevitt, Neeta Pandit‐Taskar, et al.. (2007). Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).. Blood. 110(11). 910–910. 14 indexed citations
16.
Berman, Ellin, Robert G. Maki, Martin Fleisher, et al.. (2006). Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate. New England Journal of Medicine. 354(19). 2006–2013. 217 indexed citations
17.
Maslak, P., Sudhir Gupta, Marta Gómez, et al.. (2006). Pilot trial of a synthetic breakpoint peptide vaccine in patients with chronic myeloid leukemia (CML) and minimal disease. Journal of Clinical Oncology. 24(18_suppl). 6514–6514. 1 indexed citations
18.
19.
Wieder, Robert, Steven Novick, Bruce W. Hollis, et al.. (2003). Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. Investigational New Drugs. 21(4). 445–452. 15 indexed citations
20.
Camacho, Luis H., Steven L. Soignet, Suzanne Chanel, et al.. (2000). Leukocytosis and the Retinoic Acid Syndrome in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide. Journal of Clinical Oncology. 18(13). 2620–2625. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth B. DeSantes Breakdown of academic impact, for papers by Ciara L. Freeman Breakdown of academic impact, for papers by J. Casper Breakdown of academic impact, for papers by D. J. Richel Breakdown of academic impact, for papers by Lorenzo Falchi Breakdown of academic impact, for papers by F. R. Appelbaum Breakdown of academic impact, for papers by P. Berthaud Breakdown of academic impact, for papers by Hong Xie Breakdown of academic impact, for papers by Unn‐Merete Fagerli Breakdown of academic impact, for papers by Mihaela Munteanu
Rankless by CCL
2026